|1.||Woo, Y S: 1 article (07/2015)|
|2.||Lee, D B: 1 article (07/2015)|
|3.||Bahk, W M: 1 article (07/2015)|
|4.||Xu, Wenjun: 1 article (01/2014)|
|5.||Chen, Wei: 1 article (01/2014)|
|6.||Liu, Xuan: 1 article (01/2014)|
|7.||Fang, Hong: 1 article (01/2014)|
|8.||Asai, Kuniya: 1 article (12/2009)|
|9.||Mizuno, Kyoichi: 1 article (12/2009)|
|10.||Sato, Naoki: 1 article (12/2009)|
03/01/2005 - "There was no significant difference in the antitremor effect between ZNS and arotinolol; however, ZNS was more effective for tremors of cranial nerve areas. "
07/01/2015 - "We have presented a case series of drug-induced tremors that responded well to treatment with arotinolol, which appears to be a safe and well-tolerated drug in the dose ranges used. "
07/01/2015 - "The aim of the present study is to demonstrate the effect of arotinolol on drug-induced tremor in psychiatric patients. "
07/01/2015 - "The possible utility of arotinolol to treat drug-induced tremor deserves attention and further investigation."
07/01/2015 - "Arotinolol was started to treat the tremor. "
|2.||Graves Disease (Basedow Disease)
01/20/1993 - "The purpose of this study is to clarify the effect of arotinolol (alpha 1, beta-blocker) on the thyroid functions and autonomic nerve systems (ANS) of patients with Graves' disease. "
01/20/1993 - "The reason why serum T4 levels in patients with untreated Graves' disease have decreased after the treatment of arotinolol could not be clarified. "
08/20/1993 - "[Effect of arotinolol on insulin secretion and insulin clearance rate in patients with Graves' disease]."
01/20/1993 - "In conclusion, arotinolol is a very useful drug for the initial therapy of patients with Graves' disease to reduce the serum thyroid hormone levels and symptoms of hyperthyroidism when combined with antithyroid drugs."
08/20/1993 - "Glucose-induced insulin secretion, 24-h urinary C-peptide (CPR) and euglycemic clamp were examined in five patients with hyperthyroid Graves' disease before and 2 weeks after treatment with arotinolol (20 mg/day, p.o.). "
01/20/1993 - "Arotinolol improved hyperthyroid symptoms including tachycardia, but had no effect on ANS function-tests. "
08/01/1990 - "The tachycardia was alleviated completely by either atenolol or arotinolol, but partially by carteolol. "
10/01/1989 - "The T4-induced tachycardia was alleviated completely by either atenolol or arotinolol, but only partially by carteolol. "
|4.||Coronary Stenosis (Coronary Artery Stenosis)
07/01/1990 - "Concomitantly, %SS distal to a coronary stenosis was significantly improved by arotinolol and propranolol. "
07/01/1990 - "These results indicate that arotinolol improves impaired regional myocardial function distal to a coronary stenosis in a similar manner with propranolol."
07/01/1990 - "Effects of arotinolol, a combined alpha- and beta-adrenoceptor blocking agent, on regional myocardial dysfunction produced by severe coronary stenosis in anesthetized dogs were examined and compared with those of labetalol and propranolol. "
07/01/1990 - "Comparative effects of arotinolol, labetalol and propranolol on regional myocardial dysfunction induced by flow-limiting coronary stenosis in anesthetized dogs."
01/01/1991 - "The preventive effects of long-term treatment with arotinolol on the development of cerebral stroke were examined in SHRSP fed a high salt diet. "
01/01/1991 - "Prevention of cerebral stroke by arotinolol in salt-loaded SHRSP."
01/01/1991 - "Furthermore, arotinolol (4.27 mg/kg per day) markedly inhibited the development of stroke without blood pressure reduction, when the administration was started after the onset of severe hypertension. "
01/01/1991 - "Arotinolol (4.87 mg/kg per day for 20 weeks) prevented cerebral lesions, reduced signs of stroke and delayed early mortality but did not alter blood pressure from control SHRSP, when the administration of the drug was started before the onset of hypertension. "
01/01/1991 - "These results suggest that arotinolol is more effective in preventing cerebral stroke than pindolol, labetalol and propranolol, and that factors other than blood pressure reduction may be involved in this preventive effect."
|2.||Pindolol (LB 46)
|4.||Antithyroid Agents (Antithyroid Drugs)
|7.||Adrenergic Receptors (Adrenergic Receptor)
|8.||Adrenergic Antagonists (Antiadrenergic Agents)
|10.||Carteolol (Carteolol Hydrochloride)
|1.||Cardiopulmonary Resuscitation (CPR)
|2.||Drug Therapy (Chemotherapy)